Search company, investor...

Aldea Pharmaceuticals

Founded Year



Series B | Alive

Total Raised


Last Raised

$24M | 9 yrs ago

About Aldea Pharmaceuticals

Aldea Pharmaceuticals is focused on developing small molecule modulators of the aldehyde dehydrogenase enzyme superfamily. The scientific approach was discovered by Stanford University researchers and exclusively licensed to Aldea. Aldea is pursuing treatment of clinically significant acute alcohol toxicity, Fanconi anemia and other diseases and conditions associated with toxic aldehydes.

Headquarters Location

3696 Haven Ave Suite C

Redwood City, California, 94063,

United States


Missing: Aldea Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aldea Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Aldea Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aldea Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Aldea Pharmaceuticals News

Metactive Closes $2 Million of Additional Series A Financing and Appoints David Ferrera to the Board of Directors

Feb 23, 2015

Aldea Pharmaceuticals closes m series B financing “Metactive has shown immediate, complete and lasting occlusion of large saccular aneurysms with rapid endothelialization of the aneurysm neck in a challenging nonclinical model, as well as similarly robust performance with a peripheral occlusion device,” said Tom Krol, Managing Director at KBA and a member of Metactive’s board of directors. “Clinicians treat thousands of saccular aneurysms and peripheral arteries and veins each year. We believe that Metactive’s devices have the potential to be better for patients, faster and easier for physicians to use, and less expensive for payers.” Metactive also announced today the appointment of David Ferrera to its board of directors. Ferrera is currently President and Chief Technology Officer of Blockade Medical and has 20 years of leadership experience in the medical device industry at several market-leading neurovascular firms, including MindFrame, Microvention and Micrus Endovascular. “I am pleased to have the resources to accelerate the development of our novel, potentially life-saving products and to welcome David to our board to help us realize our goal of providing physicians faster, better and less expensive options for vascular occlusion,” said F. Nicholas Franano, MD, President and CEO of Metactive. About Peripheral Artery and Aneurysm Embolization Embolization is a minimally invasive treatment that blocks the flow of blood in selected segments of arteries and veins, enabling physicians to divert blood away from cancerous tumors and other abnormal tissues, as well as from damaged or malformed segments of blood vessels. More than 150,000 peripheral vascular embolization procedures are performed each year worldwide using coils and vascular plugs. Similarly, more than 150,000 cerebral aneurysm embolization procedures are performed worldwide each year using coils and flow-diverting vascular stents. There is currently a need in these markets for endovascular embolization devices that can be placed quickly and easily, with a high degree of precision, and that result in immediate and lasting occlusion. About Metactive Medical Metactive is developing novel endovascular medical devices for the treatment of neurovascular and peripheral vascular diseases. Metactive's first products enable precise and immediate occlusion and rapid sealing of cerebral aneurysms and other target vessel segments using an over-the-wire microcatheter platform. For more information, please visit . Company Contact:

Aldea Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Aldea Pharmaceuticals founded?

    Aldea Pharmaceuticals was founded in 2008.

  • Where is Aldea Pharmaceuticals's headquarters?

    Aldea Pharmaceuticals's headquarters is located at 3696 Haven Ave, Redwood City.

  • What is Aldea Pharmaceuticals's latest funding round?

    Aldea Pharmaceuticals's latest funding round is Series B.

  • How much did Aldea Pharmaceuticals raise?

    Aldea Pharmaceuticals raised a total of $35.38M.

  • Who are the investors of Aldea Pharmaceuticals?

    Investors of Aldea Pharmaceuticals include Canaan Partners, Correlation Ventures, WuXi Healthcare Ventures and Stanford University.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.